Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/BridgeBio to present long-term data on acoramidis for ATTR-CM at ACC 2026.

BBIO

$82.33

-$0.33 -0.41%

BridgeBio to present long-term data on acoramidis for ATTR-CM at ACC 2026.

Market News

23 Mar 2026

GlobeNewsWire

View Source

Bullish

BridgeBio Pharma will share long-term efficacy and safety results of acoramidis from its ATTRibute-CM open-label extension trial at the ACC Annual Scientific Sessions in March 2026. The data highlights survival benefits and disease stabilization in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Additional posters will cover serum transthyretin levels, heart failure health status, and real-world treatment patterns. This presentation underscores BridgeBio's progress in treating genetic heart conditions and may influence future clinical use of acoramidis.

More News (BBIO)

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma remains a strong buy due to regulatory approvals for its drug acoramidis and positive clinical data for infigratinib in achondroplasia. The company expects $180.6 million in U.S. net product revenue by Q1 2026 and targets a $2.9 bill...

Analyst Insights

Bullish

3 days ago